Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Combating leukemia cells by disrupting their energy maintenance mechanism

Acute myeloid leukemia, which affects blood and bone marrow cells, is a particularly dangerous form of cancer. More than half of patients under the age of 60 die.

17 Feb 2022

A third known case of HIV remission involving stem cell transplant documented

A woman with HIV who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months despite cessation of antiretroviral therapy (ART), according to a presentation at today's Conference on Retroviruses and Opportunistic Infections (CROI).

15 Feb 2022

Molecular cage helps researchers to get atomic-level details of key cancer protein

Acute myeloid leukemia (AML), the American Cancer Institute estimates, will affect more than 20,000 Americans this year and kill more than 11,000 of them.

11 Feb 2022

New method decodes the role of DDX41 protein in preventing double-strand breaks in DNA

There are many different ways in which the genetic material DNA can be damaged, resulting in the development of diseases such as cancer. Certain forms of DNA damage are associated with so-called R-loops.

8 Feb 2022

Researchers compare survival rates of AML patients treated with two forms of transplantation methods

Acute myeloid leukemia (AML) is a common type of blood cancer that has a relatively low survival rate. It is particularly deadly for patients suffering from refractory and relapsed AML (R/R AML), meaning their cancer has stopped responding to treatment and has returned after a period of remission.

5 Jan 2022

$Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma$

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

13 Dec 2021

Novel immunotherapy shows promise for children, young adults with recurrent AML

An immunotherapy harnessing the immune system's "natural killer" cells has proven effective in treating acute myeloid leukemia (AML) in some adults whose cancers return.

12 Dec 2021

Statistical models predict outcomes for patients receiving non-intensive AML therapy

An international team has developed statistical models to predict the risk of early death in patients being treated with non-intensive therapies for acute myeloid leukemia (AML).

12 Dec 2021

Study uncovers important genetic predispositions for acute myeloid leukemia

The National Center for Tumor Diseases Dresden is a joint institution of the German Cancer Research Center, the University Hospital Carl Gustav Carus Dresden, Carl Gustav Carus Faculty of Medicine at TU Dresden and the Helmholtz-Zentrum Dresden-Rossendorf.

24 Nov 2021

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging.

22 Nov 2021

Experts develop a functional precision medicine approach to assign therapies to cancer patients

A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients' cells can be clinically useful in patients with aggressive hematological cancers.

18 Nov 2021

New research finds disturbing lack of crucial blood cancer medication

New research in the November 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA).

16 Nov 2021

NanoTCE technology shows promise for treatment of acute myeloid leukemia

Oncotarget published "Nanoparticle T cell engagers for the treatment of acute myeloid leukemia" which reported that Acute myeloid leukemia (AML) is the most common type of leukemia and has a 5-year survival rate of 25%.

12 Nov 2021

Drug combination highly effective in children with standard- and high-risk acute promyelocytic leukemia

A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.

11 Nov 2021

Researchers identify safety concerns with neuroblastoma candidate drug

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461.

9 Nov 2021

Interferon treatment coupled with bone marrow transplant reduces risk of leukemia recurrence

Researchers at the University of Michigan Health Rogel Cancer Center have identified a drug that, when given along with a bone marrow transplant, drops the risk of leukemia recurring by 20% among the high-risk patients.

21 Oct 2021

Research may lead to breakthroughs in combating cancer drug resistances

New research has revealed the differences in mechanism behind cancer’s resistance to the major class of anti-cancer drugs known as nucleoside analogues.

20 Oct 2021

Antiviral activity of wheat germ Agglutinin against SARS-CoV-2

A new study reports the antiviral activity of WGA against SARS-CoV-2 and its two Variants of Concern - Alpha and Beta.

4 Oct 2021

Novel small-molecule therapy shows promise against deadly pediatric leukemia

Mount Sinai researchers have developed a therapy that shows promise against a deadly pediatric leukemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September.

29 Sep 2021

Scientists discover novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

A new type of targeting chaperon protein HSP70 inhibitor QL47 was recently discovered by a team led by Prof. LIU Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences to treat FLT3-ITD-positive acute myeloid leukemia (AML).

27 Sep 2021